Joint pain improvement in patients on etanercept therapy for moderate to severe psoriasis

被引：0
|
作者：
Tyring, Stephen [1 ]
Kricorian, Gregory [2 ]
Gordon, Kenneth [3 ]
Klekotka, Paul [2 ]
机构：
[1] Univ Texas Houston, Houston, TX USA
[2] Amgen Inc, Thousand Oaks, CA USA
[3] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2011年 / 64卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB158 / AB158
页数：1
相关论文
共 50 条
  • [31] A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis
    Lebwohl, Mark G.
    Kircik, Leon
    Duffin, Kristina Callis
    Pariser, David
    Hooper, Michele
    Wenkert, Deborah
    Thompson, Elizabeth H. Z.
    Yang, Jun
    Kricorian, Greg
    Koo, John
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (03) : 385 - 392
  • [32] Nail psoriasis improvement is maintained in patients with moderate to severe psoriasis treated with infliximab
    Rich, P.
    Guzzo, C.
    Li, S.
    Reich, K.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB178 - AB178
  • [33] Brodalumab provides rapid improvement in psoriasis-related itch and pain in patients with moderate-to-severe plaque psoriasis
    Lebwohl, M.
    Reich, K.
    Paul, C.
    Rosen, M.
    Hansen, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 75 - 75
  • [34] The experience of pain and redness in patients with moderate to severe plaque psoriasis
    Martin, Mona L.
    Gordon, Kenneth
    Pinto, Lionel
    Bushnell, Donald M.
    Chau, Dina
    Viswanathan, Hema N.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (05) : 401 - 405
  • [35] COST EFFECTIVENESS OF TREATMENT WITH ETANERCEPT OR USTEKINUMAB FOR MODERATE TO SEVERE PSORIASIS
    Villacorta, R.
    Hay, J.
    Messali, A.
    VALUE IN HEALTH, 2012, 15 (04) : A103 - A103
  • [36] Treatment with etanercept improves patient-reported outcomes in patients with moderate to severe psoriasis
    Gottlieb, A
    Woolley, JM
    Lalla, D
    Jahreis, A
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P201 - P201
  • [37] Safety update of etanercept treatment for moderate to severe plaque psoriasis
    Campanati, Anna
    Diotallevi, Federico
    Martina, Emanuela
    Paolinelli, Matteo
    Radi, Giulia
    Offidani, Annamaria
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (04) : 439 - 448
  • [38] Characterization of etanercept pharmacokinetics, immunogenicity, and efficacy in pediatric patients with moderate to severe plaque psoriasis
    Langley, Richard G.
    Kasichayanula, Sree
    Trivedi, Mona
    Aras, Gary
    Kaliyaperumal, Arunan
    Yuraszeck, Theresa
    Gibbs, Megan
    Kricorian, Greg
    Paller, Amy S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB67 - AB67
  • [39] ECONOMIC ANALYSIS OF ETANERCEPT AS PAUSED THERAPY IN MODERATE TO SEVERE PSORIASIS FROM A PRIVATE PERSPECTIVE IN BRAZIL
    Fernandes, R. A.
    Takemoto, M. L. S.
    Amaral, L. M.
    Cruz, R. B.
    Mould, J. F.
    Fujii, R. K.
    Brandt, H.
    Almeida, G. R.
    Manfrin, D. F.
    VALUE IN HEALTH, 2012, 15 (04) : A251 - A251
  • [40] Clinically meaningful improvements in health-related quality of life from etanercept therapy for patients with moderate to severe psoriasis
    Feldman, SR
    Kimball, A
    Woolley, JM
    Zitnik, R
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P155 - P155
12345